Accelerating Clinical Development of Off-the-Shelf Cell Therapy for Liquid and Solid Tumours

Time: 5:30 pm
day: Day 1 – Track B – Evening


  • Clinical and regulatory experience with Atara’s Phase 2 and Phase 3 allogeneic T-cell therapies
  • Benefits of allogeneic approach and scaling manufacturing to meet patient needs
  • How armouring next generation allogeneic T-cell immunotherapies can overcome the hostile tumour environment